封面
市場調查報告書
商品編碼
1825321

全球脫髮症治療市場:2025年至2030年預測

Global Alopecia Treatment Market - Forecasts from 2025 to 2030

出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 149 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

脫髮症治療市場預計將從 2025 年的 51.96 億美元成長到 2030 年的 63.48 億美元,複合年成長率為 4.09%。

由於脫髮症,尤其是斑禿(一種導致過度脫髮症的自體免疫疾病)的盛行率不斷上升,脫髮症治療市場正在經歷顯著成長。不健康的飲食、久坐的生活方式、荷爾蒙變化以及包括千禧世代在內的年輕一代的壓力水平上升等因素導致脫髮發病率上升。消費者對身體健康和美麗意識的不斷增強進一步推動了這個市場的發展,這推動了對有效、微創治療的需求。來自促進研究和社會意識的組織(例如美國國家斑禿基金會(NAAF))的支持也在推動市場成長。然而,治療成本上升和新興市場准入有限等挑戰可能會阻礙市場發展。

市場促進因素

脫髮症盛行率不斷上升

脫髮症日益普遍,尤其是在年輕一代中,是市場的主要驅動力。壓力、荷爾蒙失衡和生活習慣都會加劇脫髮,從而增加了對客製化治療的需求。專注早期療育以刺激毛囊生長,正在推動創新治療方法的發展。早期治療可以顯著減輕症狀並促進頭髮生長,從而推動市場發展。

加大藥物研發投入

大量的研發投入,加上新藥的監管核准,正在推動市場強勁發展。製藥公司正優先開發新型治療方法,尤其是針對嚴重脫髮症的療法,以滿足日益成長的消費者需求。這些努力得到了強力的臨床試驗和策略性收購的支持,旨在擴大其治療組合,從而推動市場擴張。

機構支持

像NAAF這樣的非營利組織透過資助研究、提高公眾意識以及支持受影響群體,在脫髮症治療市場的發展中發揮著至關重要的作用。這些舉措加速了現代藥物的開發和核准,公眾教育宣導活動也增加了對副作用較小的治療方法的需求,進一步推動了市場成長。

地理視角

北美洲

由於脫髮患病率高且知名製藥公司眾多,以美國為首的北美預計將主導脫髮症治療市場。該地區受益於脫髮症治療領域巨額的醫療保健支出,以及對無痛有效解決方案日益成長的需求。生活方式的改變和壓力水平的上升,尤其是在千禧世代和工薪階層女性群體中,導致脫髮率上升,進一步催生了對創新護髮產品和治療方法的需求。在NAAF等機構的支持下,對研發的高度重視正在促進該地區的市場成長。

由於脫髮症盛行率的上升、藥物研發投入的增加以及強大的機構支持,脫髮症治療市場預計將大幅成長。北美,尤其是美國,憑藉著高脫髮率、強勁的醫療保健支出和積極的研究計劃,引領市場。諸如太陽製藥 (Sun Pharma) 於 2023 年收購 Concert Pharmaceuticals 等策略性舉措,凸顯了該產業對創新的關注。儘管面臨治療成本等挑戰,但該市場預計將持續成長,因為它滿足了消費者對美容和健康解決方案的需求,為製藥公司提供了開發先進治療方法的機會。

本報告的主要優點

  • 深刻分析:獲得涵蓋主要地區和新興地區的深入市場洞察,重點關注客戶群、政府政策和社會經濟因素、消費者偏好、垂直行業和其他細分市場。
  • 競爭格局:了解主要企業所採用的策略策略,並了解正確策略的市場滲透潛力。
  • 市場趨勢和促進因素:探索動態因素和關鍵市場趨勢以及它們將如何影響未來的市場發展。
  • 可行的建議:利用洞察力來制定策略決策,在動態環境中開闢新的業務流和收益。
  • 受眾廣泛:對於新興企業、研究機構、顧問、中小企業和大型企業來說,既有利又划算。

它有什麼用途?

產業與市場考量、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本支出決策、法律規範與影響、新產品開發、競爭影響

調查範圍

  • 2022 年至 2024 年的歷史數據和 2025 年至 2030 年的預測數據
  • 成長機會、挑戰、供應鏈前景、法律規範與趨勢分析
  • 競爭定位、策略和市場佔有率分析
  • 收益成長和預測細分市場和區域分析(包括國家)
  • 公司概況(尤其是財務狀況和關鍵發展)。

目錄

第1章執行摘要

第2章市場概述

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔

第3章 經營狀況

  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 波特五力分析
  • 產業價值鏈分析
  • 政策法規
  • 策略建議

第4章 技術展望

第5章全球脫髮症治療市場(按症狀)

  • 介紹
  • 脫髮症
  • 全脫髮症
  • 全身性脫髮症
  • 雄性脫髮症
  • 脫髮症
  • 其他

第6章全球脫髮症治療市場(按藥物類型)

  • 介紹
  • 口服藥物
  • 外用藥物
  • 注射
  • 其他

第7章全球脫髮症治療市場(按地區)

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 其他
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 印尼
    • 泰國
    • 其他

第8章競爭格局及分析

  • 主要企業和策略分析
  • 市佔率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第9章:公司簡介

  • Eli Lilly and Company
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Cipla
  • HCell Inc.
  • Daiichi Sankyo Inc.
  • Johnson & Johnson
  • GlaxoSmithKline plc

第10章 附錄

  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要利益
  • 調查方法
  • 簡稱
簡介目錄
Product Code: KSI061613781

The global alopecia treatment market is expected to grow from USD 5.196 billion in 2025 to USD 6.348 billion in 2030, at a CAGR of 4.09%.

The global alopecia treatment market is experiencing significant growth, driven by the increasing prevalence of alopecia, particularly alopecia areata, an autoimmune disorder causing excessive hair loss. Factors such as unhealthy diets, sedentary lifestyles, hormonal changes, and rising stress levels among younger populations, including millennials, are contributing to the growing incidence of hair loss. The market is further propelled by heightened consumer awareness of physical well-being and aesthetic beauty, which is increasing demand for effective, minimally invasive treatments. Support from institutions like the National Alopecia Areata Foundation (NAAF) in the United States, which promotes research and public awareness, also bolsters market growth. However, challenges such as the high cost of treatments and limited accessibility in developing regions may pose constraints to market expansion.

Market Drivers

Rising Prevalence of Alopecia

The growing incidence of alopecia, particularly among younger demographics, is a primary driver of the market. Stress, hormonal imbalances, and lifestyle factors are exacerbating hair loss, prompting demand for well-designed treatments. The focus on early intervention to stimulate hair follicle growth is driving the development of innovative therapies, as early-stage treatment can significantly reduce symptoms and promote hair regrowth, fueling market growth.

Improved Investment in Drug Development

Significant investments in research and development, coupled with regulatory approvals for new drugs, are providing a strong impetus for market growth. Pharmaceutical companies are prioritizing the development of novel treatments for alopecia, particularly for severe cases, to meet rising consumer demand. These efforts are supported by robust clinical trials and strategic acquisitions aimed at enhancing treatment portfolios, driving market expansion.

Institutional Support

Non-profit organizations like the NAAF play a crucial role in advancing the alopecia treatment market by funding research, raising awareness, and supporting affected communities. These initiatives encourage the development and approval of modern medicines, while public education efforts increase demand for treatments with minimal side effects, further propelling market growth.

Geographical Outlook

North America

North America, led by the United States, is expected to dominate the alopecia treatment market due to the high prevalence of hair loss and the presence of well-established pharmaceutical companies. The region benefits from significant healthcare spending on alopecia treatments and a growing demand for painless, effective solutions. Changing lifestyles, particularly among millennials and working-class women, coupled with rising stress levels, are driving hair loss rates, further increasing the need for innovative hair care products and treatments. The strong focus on research and development, supported by organizations like the NAAF, enhances market growth in the region.

Key Developments

In March 2023, Sun Pharma acquired Concert Pharmaceuticals to advance the development of treatments for alopecia areata. This strategic acquisition aims to strengthen Sun Pharma's portfolio by promoting drugs tailored to address the needs of individuals with this condition, reflecting the industry's commitment to innovation and market expansion.

The alopecia treatment market is poised for considerable growth, driven by the rising prevalence of alopecia, increased investments in drug development, and strong institutional support. North America, particularly the U.S., leads the market due to high hair loss rates, robust healthcare spending, and active research initiatives. Strategic moves like Sun Pharma's 2023 acquisition of Concert Pharmaceuticals highlight the industry's focus on innovation. Despite challenges such as treatment costs, the market's alignment with consumer demand for aesthetic and health-focused solutions positions it for sustained expansion, offering opportunities for pharmaceutical companies to develop advanced therapies.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Segmentation:

By Condition Type

  • Alopecia Areata
  • Alopecia Totalis
  • Alopecia Universalis
  • Androgenetic Alopecia
  • Ciactricial Alopecia
  • Others

By Medication Type

  • Oral
  • Topical
  • Injectable
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL ALOPECIA TREATMENT MARKET BY CONDITION TYPE

  • 5.1. Introduction
  • 5.2. Alopecia Areata
  • 5.3. Alopecia Totalis
  • 5.4. Alopecia Universalis
  • 5.5. Androgenetic Alopecia
  • 5.6. Ciactricial Alopecia
  • 5.7. Others

6. GLOBAL ALOPECIA TREATMENT MARKET BY MEDICATION TYPE

  • 6.1. Introduction
  • 6.2. Oral
  • 6.3. Topical
  • 6.4. Injectable
  • 6.5. Others

7. GLOBAL ALOPECIA TREATMENT MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. USA
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. Germany
    • 7.4.2. France
    • 7.4.3. United Kingdom
    • 7.4.4. Spain
    • 7.4.5. Others
  • 7.5. Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. UAE
    • 7.5.3. Others
  • 7.6. Asia Pacific
    • 7.6.1. China
    • 7.6.2. India
    • 7.6.3. Japan
    • 7.6.4. South Korea
    • 7.6.5. Indonesia
    • 7.6.6. Thailand
    • 7.6.7. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. Eli Lilly and Company
  • 9.2. Pfizer Inc.
  • 9.3. Sun Pharmaceutical Industries Ltd.
  • 9.4. Cipla
  • 9.5. HCell Inc.
  • 9.6. Daiichi Sankyo Inc.
  • 9.7. Johnson & Johnson
  • 9.8. GlaxoSmithKline plc

10. APPENDIX

  • 10.1. Currency
  • 10.2. Assumptions
  • 10.3. Base and Forecast Years Timeline
  • 10.4. Key benefits for the stakeholders
  • 10.5. Research Methodology
  • 10.6. Abbreviations